Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equity - USD ($) $ in Thousands	Total	Series A Non-Voting Convertible Preferred Stock	Series B Non-Voting Convertible Preferred Stock	Common Stock	Preferred Stock Series A Non-Voting Convertible Preferred Stock	Preferred Stock Series B Non-Voting Convertible Preferred Stock	Common Stock	Common Stock Series A Non-Voting Convertible Preferred Stock	Common Stock Common Stock	Additional Paid-in Capital	Additional Paid-in Capital Series A Non-Voting Convertible Preferred Stock	Additional Paid-in Capital Common Stock	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022						0
Beginning balance at Dec. 31, 2022						$ 0
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of Series B non-voting convertible preferred stock in connection with private placement, net of financing costs (in shares)						150,000
Issuance of Series B non-voting convertible preferred stock in connection with private placement, net of financing costs						$ 84,555
Ending balance (in shares) at Dec. 31, 2023						150,000
Ending balance at Dec. 31, 2023						$ 84,555
Beginning balance (in shares) at Dec. 31, 2022					0	0
Beginning balance (in shares) at Dec. 31, 2022							2,614,000
Beginning balance at Dec. 31, 2022	$ 50,305				$ 0	$ 0	$ 6			$ 475,971			$ (48)	$ (425,624)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock in connection with private placement, net of financing costs (in shares)					721,000				6,000,000
Issuance of stock in connection with private placement, net of financing costs		$ 197,364		$ 84,555	$ 197,364							$ 84,555
Issuance of Series A non-voting convertible preferred stock in connection with the asset acquisition of Spyre and settlement of related forward contract (in shares)					365,000
Issuance of Series A non-voting convertible preferred stock in connection with the asset acquisition of Spyre and settlement of related forward contract		189,741			$ 189,741
Conversion of non-voting convertible preferred stock into common stock (in shares)					(649,000)			25,972,000
Conversion of non-voting convertible preferred stock into common stock		0			$ (202,178)			$ 3			$ 202,175
Issuance of common stock in connection with the asset acquisition of Spyre (in shares)							518,000
Issuance of common stock in connection with the asset acquisition of Spyre	3,768						$ 1			3,767
Issuance of common stock in connection with exercise of pre-funded warrants (in shares)							905,000
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)							48,000
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan	405									405
CVR distribution to common stockholders	(29,500)									(29,500)
Stock-based compensation expense	14,347									14,347
Issuance of Parapyre Option Obligation warrants	11,471									11,471
Foreign currency translation adjustment	37												37
Unrealized gain (loss) on marketable securities	313												313
Net loss	(338,790)	$ (239,158)	$ (4,749)	(94,883)										(338,790)
Ending balance (in shares) at Dec. 31, 2023		437,037			437,000	0
Ending balance (in shares) at Dec. 31, 2023							36,057,000
Ending balance at Dec. 31, 2023	184,016				$ 184,927	$ 0	$ 10			763,191			302	(764,414)
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of Series B non-voting convertible preferred stock in connection with private placement, net of financing costs (in shares)						122,000
Issuance of Series B non-voting convertible preferred stock in connection with private placement, net of financing costs						$ 168,850
Stockholder approval of the issuance of common stock upon conversion of Series B convertible non-voting preferred stock (in shares)						(272,000)
Stockholder approval of the issuance of common stock upon conversion of Series B convertible non-voting preferred stock						$ (253,405)
Ending balance (in shares) at Dec. 31, 2024						0
Ending balance at Dec. 31, 2024						$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of non-voting convertible preferred stock into common stock (in shares)						(255,000)	10,198,000
Conversion of non-voting convertible preferred stock into common stock	0					$ (244,010)	$ 1			244,009
Issuance of common stock in connection with exercise of pre-funded warrants (in shares)							250,000
Issuance of common stock in connection with exercise of pre-funded warrants	1									1
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)							931,000
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan	7,511									7,511
CVR distribution to common stockholders (in shares)							38,000
Stock-based compensation expense	30,374									30,374
Issuance of Parapyre Option Obligation warrants	14,459									14,459
Foreign currency translation adjustment	4												4
Unrealized gain (loss) on marketable securities	(126)												(126)
Stockholder approval of the issuance of common stock upon conversion of Series B convertible non-voting preferred stock (in shares)						272,000
Stockholder approval of the issuance of common stock upon conversion of Series B convertible non-voting preferred stock	253,405					$ 253,405
Exchange of Series A non-voting convertible preferred stock for common stock (in shares)					(91,000)		3,640,000
Exchange of Series A non-voting convertible preferred stock for common stock	0				$ (38,502)		$ 1			38,501
Issuance of common stock in connection with at-the-market offering program, net of financing costs (in shares)							777,000
Issuance of common stock in connection with at-the-market offering program, net of financing costs	20,504									20,504
Issuance of common stock in connection with follow-on offering, net of financing costs (in shares)							8,366,000
Issuance of common stock in connection with follow-on offering, net of financing costs	215,674						$ 1			215,673
Net loss	$ (208,018)	$ (47,624)	$ (10,839)	(149,555)										(208,018)
Ending balance (in shares) at Dec. 31, 2024		346,045	16,667		346,000	17,000
Ending balance (in shares) at Dec. 31, 2024	60,257,023						60,257,000
Ending balance at Dec. 31, 2024	$ 517,804				$ 146,425	$ 9,395	$ 13			1,334,223			180	(972,432)
Ending balance (in shares) at Dec. 31, 2025						0
Ending balance at Dec. 31, 2025						$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)							354,000
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan	3,306									3,306
Stock-based compensation expense	37,614									37,614
Foreign currency translation adjustment	(22)												(22)
Unrealized gain (loss) on marketable securities	711												711
Issuance of common stock in connection with at-the-market offering program, net of financing costs (in shares)							446,000
Issuance of common stock in connection with at-the-market offering program, net of financing costs	14,745									14,745
Issuance of common stock in connection with follow-on offering, net of financing costs (in shares)							17,095,000
Issuance of common stock in connection with follow-on offering, net of financing costs	296,281						$ 2			296,279
Vesting of restricted stock units (in shares)							38,000
Net loss	$ (155,203)	$ (27,344)	$ (1,317)	$ (126,541)										(155,203)
Ending balance (in shares) at Dec. 31, 2025		346,045	16,667		346,000	17,000
Ending balance (in shares) at Dec. 31, 2025	78,189,811						78,190,000
Ending balance at Dec. 31, 2025	$ 715,236				$ 146,425	$ 9,395	$ 15			$ 1,686,167			$ 869	$ (1,127,635)